Abbott Laboratories $ABT Stock Holdings Cut by Wellington Management Group LLP

Key Points

• Wellington Management trimmed its stake in Abbott by 7.2% in Q3, holding 23,246,144 shares (~1.34% of the company) worth about $3.11 billion, and institutional investors now own roughly 75.18% of the stock.
• Abbott reported Q4 EPS of $1.50 (in line with estimates) but revenue of $11.46 billion missed expectations, and the company guided Q1 2026 EPS to $1.120–1.180 and FY 2026 EPS to $5.550–5.800.
• The stock carries a consensus rating of Moderate Buy with an average target of $136.16 amid several recent price-target cuts, and it pays a $0.63 quarterly dividend (2.3% yield; ex-dividend Apr 15).

Wellington Management Group LLP lessened its position in Abbott Laboratories (NYSE:ABT - Free Report) by 7.2% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 23,246,144 shares of the healthcare product maker's stock after selling 1,804,435 shares during the period. Wellington Management Group LLP owned approximately 1.34% of Abbott Laboratories worth $3,113,589,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Brighton Jones LLC lifted its position in shares of Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock valued at $5,850,000 after acquiring an additional 4,755 shares during the last quarter. Sivia Capital Partners LLC grew its holdings in shares of Abbott Laboratories by 3.5% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker's stock worth $648,000 after acquiring an additional 162 shares during the last quarter. United Bank raised its position in shares of Abbott Laboratories by 7.4% during the second quarter. United Bank now owns 29,004 shares of the healthcare product maker's stock worth $3,945,000 after purchasing an additional 2,001 shares during the period. ABN Amro Investment Solutions purchased a new stake in shares of Abbott Laboratories during the second quarter valued at $2,790,000. Finally, Thompson Davis & CO. Inc. acquired a new position in shares of Abbott Laboratories in the 2nd quarter valued at $255,000. Institutional investors own 75.18% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. William Blair raised Abbott Laboratories to a "strong-buy" rating in a research note on Thursday, November 20th. Raymond James Financial decreased their target price on shares of Abbott Laboratories from $146.00 to $130.00 and set an "outperform" rating for the company in a report on Friday, January 23rd. Weiss Ratings downgraded shares of Abbott Laboratories from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Monday, January 26th. Barclays reduced their price target on shares of Abbott Laboratories from $169.00 to $142.00 and set an "overweight" rating for the company in a research report on Monday, February 2nd. Finally, Royal Bank Of Canada decreased their price objective on shares of Abbott Laboratories from $147.00 to $135.00 and set an "outperform" rating for the company in a research note on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $136.16.

Abbott Laboratories Price Performance

NYSE ABT opened at $107.99 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. The firm has a market capitalization of $187.66 billion, a price-to-earnings ratio of 29.03, a price-to-earnings-growth ratio of 1.72 and a beta of 0.74. The company has a 50 day simple moving average of $114.58 and a 200-day simple moving average of $123.91. Abbott Laboratories has a 52-week low of $105.27 and a 52-week high of $139.06.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting analysts' consensus estimates of $1.50. The firm had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The firm's revenue was up 4.4% on a year-over-year basis. During the same period in the previous year, the firm posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories's payout ratio is currently 67.74%.

Insiders Place Their Bets

In related news, VP John A. Jr. Mccoy sold 585 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $67,614.30. Following the completion of the sale, the vice president directly owned 24,628 shares in the company, valued at approximately $2,846,504.24. This trade represents a 2.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Daniel J. Starks bought 10,000 shares of the stock in a transaction on Wednesday, February 4th. The stock was purchased at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the purchase, the director directly owned 6,738,817 shares of the company's stock, valued at approximately $732,711,572.41. This represents a 0.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders sold a total of 3,055 shares of company stock valued at $353,097 in the last three months. Company insiders own 0.46% of the company's stock.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.